Effects of Vitamin D On Cisplatin Induced Heart and Lung Toxicity in Albino Rat
Background: While Cisplatin (CP) is a powerful DNA alkylating agent used to treat many malignancies, its clinical use is linked to a number of negative side effects. It has been proposed that vitamin D can shield biological systems against harm caused by CP. The current study's objective was to...
Gespeichert in:
Veröffentlicht in: | International journal of anatomy and research 2022-12, Vol.10 (4), p.8512-8522 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background: While Cisplatin (CP) is a powerful DNA alkylating agent used to treat many malignancies, its clinical use is linked to a number of negative side effects. It has been proposed that vitamin D can shield biological systems against harm caused by CP. The current study's objective was to look into how vitamin D protects the rat heart and lung against cisplatin-induced damage. Material and methods: Thirty adult male Albino rats; 180–220 g body weight were allocated into 3 groups; Group I (n=10) receiving saline, Group II (n=10); rats receiving CP (single dose of 6.5 mg/kg intraperitoneal) and Group III (n=10); receiving CP and 50 ng/kg/day alfacalcidol. Results: Alterations included a significant increase in malondialdehyde (MDA) level in the CP group compared with the other groups (p value for comparing between control and each other group, statistically significant at p ≤ 0.05). Histopathologically, CP induced severe changes were observed. However, the CP-induced disturbances significantly improved by treatment with Vitamin D. Conclusion: According to this study, CP treatment significantly harmed rats' hearts and lungs; however, treatment with vitamin D significantly lessened these harms. Keywords: Cisplatin, Immunohistochemical, Vitamin D, Malondialdehyde, Oxidative stress. |
---|---|
ISSN: | 2321-8967 2321-4287 |
DOI: | 10.16965/ijar.2022.252 |